Lab-Grown mini tumors could guide pancreatic cancer treatment

NCT ID NCT06813079

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether growing miniature versions of a patient's own pancreatic tumor in the lab (called organoids) can help doctors choose the most effective drug for that individual. About 25 adults with advanced, inoperable pancreatic cancer will have their tumor organoids tested against two drugs, cobimetinib and ponatinib. The goal is to see if this personalized approach leads to tumor shrinkage or better disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cobimetinib and Ponatinib
What this could lead to: If successful, this approach could make treatment for advanced pancreatic cancer more personalized and effective, potentially improving survival and quality of life.
What could go wrong: This is a small, early-phase trial (25 participants) testing a new method. The drugs may not work for everyone, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma epithelial neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER EPITHELIAL TUMOR PANCREATIC DUCTAL CARCINOMA

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.